Additional Information

Description

Xolair 150 mg SDV (Single-Dose Vial) is a medication primarily used to treat severe allergic asthma and chronic idiopathic urticaria (chronic hives) in patients who have not responded adequately to conventional treatments. This injectable formulation contains 150 mg of omalizumab, a monoclonal antibody that specifically targets and neutralizes immunoglobulin E (IgE), a key mediator of allergic reactions.

Administered via subcutaneous injection, Xolair works by binding to IgE antibodies circulating in the bloodstream, thereby preventing them from triggering allergic responses such as airway inflammation in asthma or skin reactions in chronic hives. This mechanism helps reduce the frequency and severity of asthma exacerbations and hives episodes, improving overall symptom control and quality of life for patients.

Each single-dose vial is intended for individual use and is sterilely packaged to maintain product integrity and safety. Healthcare providers carefully determine the appropriate dosage and injection schedule based on the patient's body weight and specific medical condition. Regular monitoring is typically recommended to assess treatment effectiveness and adjust therapy as needed.